Albuterol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1981
- First approval year
- 1981
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Albuterol
- Molecular weight
- 239.31
- Structure (SMILES)
- CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
- aerolin
- Aerolin
- aerolin 400
- Aerolin 400
- aerolin auto
- Aerolin auto
- airomir
- Airomir
- airsalb
- Airsalb
- albuterol
- Albuterol
- asmasal clickhaler
- Asmasal clickhaler
- asmasal spacehaler
- Asmasal spacehaler
- asmaven
- Asmaven
- asmavent
- Asmavent
- cobutolin
- Cobutolin
- combivent
- Combivent
- combivent udvs
And 37 more, listed on the interactive page.
- (±)-1,3-BENZENEDIMETHANOL, .ALPHA.(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-
- 1 3 benzenedimethanol alpha sup 1 1 1 dimethylethyl amino methyl 4 hydroxy
- 1,3-BENZENEDIMETHANOL, .ALPHA.(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-
- albuterol
- Albuterol
- ALBUTEROL [HSDB]
- ALBUTEROL [MI]
- ALBUTEROL [ORANGE BOOK]
- ALBUTEROL [USAN]
- ALBUTEROL [USP MONOGRAPH]
- ALBUTEROL [USP-RS]
- ALBUTEROL [VANDF]
- Albuterol 90 mcg /salbutamol 100 mcg HFA MDI
- albuterol 90 mcg salbutamol 100 mcg hfa mdi
- albuterol hsdb
- albuterol mi
- albuterol orange book
- albuterol usan
- albuterol usp monograph
- albuterol usp rs
- albuterol vandf
- combivent
- Combivent
- duoneb
- Duoneb
And 27 more, listed on the interactive page.
- CAS registry numbers
- 18559-94-9
- ChEMBL ID
- CHEMBL714
- InChIKey
- NDAUXUAQIAJITI-UHFFFAOYSA-N
- PubChem compound IDs
- 2083
- FDA ingredient codes (UNII)
- QF8SVZ843E
- R03AC02
- R03CC02
Sources for recorded values
- 435
- 142153
- Applicant
- GLAXOSMITHKLINE
- Approval date
- 19 Apr 2001
- Application number
- NDA020983
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- salbutamol
- Type
- Synthetic organic
- Drug name stem
- -terol
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- topical
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
- Protein identifier
- P07550
- Action type
- PARTIAL_AGONIST
- Target
- β<sub>1</sub>-adrenoceptor
- Gene symbol
- β<sub>1</sub>-adrenoceptor
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pEC50
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β1-adrenoceptor
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Affinity units
- pEC50
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β1-adrenoceptor
- Gene symbol
- ADRB1
- Protein identifier
- P08588
- Affinity units
- pKi
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β3-adrenoceptor
- Gene symbol
- ADRB3
- Protein identifier
- P13945
- Affinity units
- pEC50
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β3-adrenoceptor
- Gene symbol
- ADRB3
- Protein identifier
- P13945
- Affinity units
- pKi
Open Targets mechanisms
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Heart Failure
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Memory Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001072
- Subject identifier
- D008569
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
- Condition
- Heart Failure
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Lung Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Rhinitis, Allergic, Seasonal
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003956
- Subject identifier
- D006255
- Condition
- Status Asthmaticus
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008590
- Subject identifier
- D013224
- Condition
- Respiratory Insufficiency
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009686
- Subject identifier
- D012131
- Condition
- Tachypnea
- Highest recorded phase
- 1
- Condition identifier
- EFO:0009840
- Subject identifier
- D059246
- Condition
- Organophosphate Poisoning
- Highest recorded phase
- 3
- Condition identifier
- EFO:0010581
- Subject identifier
- D062025
- Condition
- Pulmonary Edema
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001134
- Subject identifier
- D011654
- Condition
- Abdominal Pain
- Highest recorded phase
- 3
- Condition identifier
- HP:0002027
- Subject identifier
- D015746
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Bronchiolitis
- Highest recorded phase
- 2
- Condition identifier
- HP:0011950
- Subject identifier
- D001988
- Condition
- Cough
- Highest recorded phase
- 2
- Condition identifier
- HP:0012735
- Subject identifier
- D003371
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- HP:4000007
- Subject identifier
- D001986
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Asthma, Exercise-Induced
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001250
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001986
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005149
- Subject identifier
- D006976
- Condition
- Hypersensitivity
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005271
- Subject identifier
- D006967
- Condition
- Lymphangioleiomyomatosis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0011705
- Subject identifier
- D018192
And 6 more, listed on the interactive page.
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000373
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001072
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001361
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003818
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003956
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004991
- Condition identifier
- EFO_0005414
- Condition identifier
- EFO_0008590
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009686
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009909
- Condition identifier
- EFO_0010581
- Highest recorded phase
- 3
- Condition identifier
- EFO_0803536
- Condition identifier
- HP_0001513
- Highest recorded phase
- 1
- Condition identifier
- HP_0002027
- Highest recorded phase
- 3
- Condition identifier
- HP_0002093
- Highest recorded phase
- 2
- Condition identifier
- HP_0002153
- Condition identifier
- HP_0003712
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0006536
- Highest recorded phase
- 4
- Condition identifier
- HP_0012418
- Highest recorded phase
- 2
- Condition identifier
- HP_0012735
- Highest recorded phase
- 2
And 48 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
Open Targets warnings
- Warning
- Black Box Warning
- Country
- United States
- Event
- asthma
- Reports
- 2,513
- Reporting signal score
- 7,684.77
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 60
- Reporting signal score
- 275.453
- Event
- blood calcium decreased
- Reports
- 118
- Reporting signal score
- 198.582
- Event
- blood count abnormal
- Reports
- 492
- Reporting signal score
- 1,338.15
- Event
- blood test abnormal
- Reports
- 189
- Reporting signal score
- 434.338
- Event
- breath sounds abnormal
- Reports
- 133
- Reporting signal score
- 372.115
- Event
- bronchial obstruction
- Reports
- 71
- Reporting signal score
- 225.463
- Event
- bronchial secretion retention
- Reports
- 46
- Reporting signal score
- 155.888
- Event
- bronchial wall thickening
- Reports
- 59
- Reporting signal score
- 226.743
- Event
- bronchiectasis
- Reports
- 162
- Reporting signal score
- 420.582
- Event
- bronchitis
- Reports
- 222
- Reporting signal score
- 174.833
- Event
- bronchospasm
- Reports
- 116
- Reporting signal score
- 145.358
- Event
- bronchospasm paradoxical
- Reports
- 34
- Reporting signal score
- 138.147
- Event
- chest discomfort
- Reports
- 559
- Reporting signal score
- 747.109
- Event
- chronic obstructive pulmonary disease
- Reports
- 440
- Reporting signal score
- 838.645
- Event
- chronic sinusitis
- Reports
- 59
- Reporting signal score
- 137.349
- Event
- cognitive disorder
- Reports
- 175
- Reporting signal score
- 174.46
- Event
- cough
- Reports
- 1,245
- Reporting signal score
- 1,597.3
- Event
- creatinine renal clearance decreased
- Reports
- 114
- Reporting signal score
- 256.254
- Event
- device delivery system issue
- Reports
- 134
- Reporting signal score
- 502.799
- Event
- dyspnoea
- Reports
- 2,591
- Reporting signal score
- 3,298.17
- Event
- dyspnoea exertional
- Reports
- 241
- Reporting signal score
- 334.566
- Event
- emphysema
- Reports
- 105
- Reporting signal score
- 233.26
- Event
- eosinophil count increased
- Reports
- 151
- Reporting signal score
- 328.01
- Event
- eosinophilia
- Reports
- 145
- Reporting signal score
- 181.459
And 41 more, listed on the interactive page.
- NCT00000577
- NCT00310401
- NCT00354354
- NCT00358488
- NCT00359788
- NCT00388882
- NCT00400153
- NCT00549120
- NCT00665600
- NCT00911651
- NCT01019694
- NCT01120691
- NCT01253473
- NCT01313494
- NCT01323621
- NCT01490125
- NCT01613326
- NCT01691482
- NCT01706328
- NCT01922271
- NCT01969539
- NCT02103374
- NCT02177253
- NCT02182674
- NCT02182856
And 50 more, listed on the interactive page.
- Dose
- 3 mL
- Route
- Inhalation
- How often
- 4 times daily, up to 2 additional doses per day if needed
- Administered via nebulization with jet nebulizer connected to an air compressor
- Use with face mask or mouthpiece
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 4
- Polar surface area
- 72.72
- Calculated partition coefficient (ALogP)
- 1.31
- Calculated partition coefficient (XLogP)
- 0.3
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 17
- Molecular formula
- C13H21NO3
- Monoisotopic mass
- 239.15214353
- Natural product
- Yes
- Recorded assays
- 3,006
- Active assays
- 94
- Confirmatory
- Other
- Screening
- Summary
- Bronchodilator Agents
- Tocolytic Agents
- Adrenergic beta-2 Receptor Agonists
Distribution coefficient (LogD)
- Median
- -2.69
- Mean
- -2.69
- Minimum
- -2.69
- Maximum
- -2.69
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 49
- Mean
- 49
- Minimum
- 49
- Maximum
- 49
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (325)
- 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- 5 Versus 10 Units of Insulin in Hyperkalemia Management
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
- A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
- A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:
- A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma
- A Comparison of Combivent UDV (Ipratropium 500mcg and Salbutamol 2.5mg) and Salbutamol UDV Alone (2.5mg)
- A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)
- A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma
- A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
- A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
- A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis
- A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma
Approved for (3)
In development for (32)
- Acute bronchiolitis Phase 2
- Acute respiratory distress syndrome Phase 1
- Allergic asthma Phase 2
- Allergic disease Phase 2
- Amyotrophic lateral sclerosis Phase 2
- Bronchiolitis Phase 2
- Congenital myasthenic syndrome Phase 1
- Congestive heart failure Phase 3
- Diabetes mellitus Phase 1
- Glycogen storage disease II Phase 1
- Heart failure Phase 3
- Heritable pulmonary arterial hypertension Phase 2
- Idiopathic pulmonary arterial hypertension Phase 2
- Idiopathic pulmonary fibrosis Phase 1
- Lung disorder Phase 3
- Lymphangioleiomyomatosis Phase 1
- Major depressive disorder Phase 1
- Myasthenia gravis Phase 2
- Obesity disorder Phase 1
- Obsolete idiopathic pulmonary arterial hypertension Phase 2
Other linked conditions (12)
- Bronchial disorder
- Chronic kidney disease
- Chronic renal failure syndrome
- Congenital myopathy
- COVID-19
- Cystic fibrosis
- Facioscapulohumeral muscular dystrophy
- Multiple sclerosis
- Pneumonia
- Pneumothorax
- Pulmonary emphysema
- Squamous cell lung carcinoma